ex vivo generated megakaryocytic progenitors

Ex vivo generated megakaryocytic progenitors are an autologous cell therapy designed to accelerate platelet recovery in cancer patients undergoing high-dose chemotherapy and autologous peripheral blood progenitor cell (PBPC) transplantation. The therapy is produced by isolating CD34+ hematopoietic progenitor cells from a patient's apheresis product and culturing them for approximately seven days in a serum-free medium. This culture is supplemented with a specific cytokine cocktail—including megakaryocyte growth and development factor (MGDF), stem cell factor (SCF), interleukin-3 (IL-3), IL-6, IL-11, FLT-ligand, and macrophage inflammatory protein-1α (MIP-1α)—to induce lineage-specific proliferation and commitment to the megakaryocytic pathway. Upon reinfusion, these progenitors (characterized by CD34+/CD61+ expression) differentiate into mature megakaryocytes in vivo, facilitating the endogenous production of platelets and potentially reducing the requirement for allogeneic platelet transfusions.

Other names

autologous megakaryocytic progenitorsMPex vivo expanded megakaryocytic progenitorscultured megakaryocytic progenitors